Glimstic G1 is a bilayered smart tablet specifically formulated for the effective management of type 2 diabetes mellitus. This innovative combination includes Glimepiride (1 mg) and Metformin (500 mg) sustained release (SR), designed to provide a comprehensive approach to controlling blood glucose levels in patients with diabetes.
Glimepiride, a member of the sulfonylurea class, works by stimulating the pancreas to release insulin, which is essential for lowering blood sugar levels. This mechanism is particularly effective in managing postprandial glucose levels, helping to prevent spikes in blood sugar after meals. Metformin, on the other hand, is a biguanide that enhances insulin sensitivity in peripheral tissues and reduces hepatic glucose production. The sustained release formulation of Metformin ensures a gradual release of the medication, which helps maintain stable blood glucose levels throughout the day while minimizing gastrointestinal side effects.
The combination of Glimepiride and Metformin in Glimstic G1 not only aids in achieving better glycemic control but also helps reduce the risk of diabetes-related complications. This dual-action approach is especially beneficial for patients who may not achieve adequate control with Metformin alone. By addressing multiple pathways involved in glucose regulation, Glimstic G1 provides a more effective solution for managing type 2 diabetes.
